2026-04-13T13:42:00Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1338372025-12-05T04:21:37Zcom_2072_1057col_2072_478809col_2072_478917

00925njm 22002777a 4500 dc Sicras Mainar, Antoni author Rejas, Javier author Pérez-Paramo, Maria author Sánchez-Álvarez, Luis author Navarro-Artieda, Ruth author Darbà, Josep author 2019-05-24T07:41:51Z 2020-02-28T06:10:17Z 2019-02 2019-05-24T07:41:51Z Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...) Medicaments Medicaments genèrics Anàlisi cost-benefici Neuropsicofarmacologia Tractament del dolor Ansietat Drugs Generic drugs Cost effectiveness Neuropsychopharmacology Pain treatment Anxiety Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin